Glenmark Life Sciences Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

24.51

24.51

1.96

1.96

0.46

Share application money

6.68

3.50

-

-

-

Preference share capital

-

-

-

-

1.50

Reserves & surplus

2,107.02

2,026.31

750.79

399.73

86.17

Loan funds

Secured loans

-

-

-

0.02

0.02

Unsecured loans

-

-

-

-

-

Total

2,138.21

2,054.31

752.75

401.71

88.15

Uses of funds

Fixed assets

Gross block

932.25

708.02

650.08

593.74

475.05

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

151.62

112.99

77.28

47.50

18.75

Net block

780.63

595.03

572.80

546.25

456.31

Capital work-in-progress

61.62

91.69

14.10

10.73

80.39

Investments

0.08

0.08

0.08

0.08

0.08

Net current assets

Current assets, loans & advances

1,859.83

1,784.21

1,410.10

1,168.55

938.62

Less : current liabilities & provisions

563.94

416.70

1,244.33

1,323.89

1,387.25

Total net current assets

1,295.89

1,367.52

165.77

-155.34

-448.63

Miscellaneous expenses not written

-

-

-

-

-

Total

2,138.21

2,054.31

752.75

401.71

88.15

Notes:

Book value of unquoted investments

0.08

0.08

0.08

0.08

0.08

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

12.83

50.42

17.23

38.93

187.29

Number of equity sharesoutstanding (Lacs)

1225.27

1225.27

98.00

19.60

4.60